Rituximab Treatment for Relapsed Autoimmune Hemolytic Anemia in Evans Syndrome

Anat Galor; Timothy O'Brien

doi:10.1007/BF02983558

Rituximab Treatment for Relapsed Autoimmune Hemolytic Anemia in Evans Syndrome

Anat Galor, Timothy O'Brien

Research output: Contribution to journal › Article

18 Scopus citations

Abstract

A case is reported of idiopathic relapsed autoimmune hemolytic anemia successfully treated with rituximab. A 43-year-old white male patient with past medical history of Evans syndrome was found to have recurrent autoimmune hemolytic anemia. Previous treatments included steroids, splenectomy, intravenous immunoglobulin, plasmapheresis, staphylococcal Protein A immunoadsorption (Prosorba column), and chemotherapeutic agents (cytoxan and vincristine). Rituximab was given weekly at 375 mg/m² for 4 doses. The drug was well tolerated and the patient remains in remission 9 months after completion of therapy.

Original language	English (US)
Pages (from-to)	335-336
Number of pages	2
Journal	International journal of hematology
Volume	78
Issue number	4
DOIs	https://doi.org/10.1007/BF02983558
State	Published - Nov 2003
Externally published	Yes

Fingerprint

Keywords

Immune hemolytic anemia
Rituximab

ASJC Scopus subject areas

Hematology

Cite this

Galor, A., & O'Brien, T. (2003). Rituximab Treatment for Relapsed Autoimmune Hemolytic Anemia in Evans Syndrome. International journal of hematology, 78(4), 335-336. https://doi.org/10.1007/BF02983558

@article{ae511391ab4b4ed29199623ce03ce861,

title = "Rituximab Treatment for Relapsed Autoimmune Hemolytic Anemia in Evans Syndrome",

abstract = "A case is reported of idiopathic relapsed autoimmune hemolytic anemia successfully treated with rituximab. A 43-year-old white male patient with past medical history of Evans syndrome was found to have recurrent autoimmune hemolytic anemia. Previous treatments included steroids, splenectomy, intravenous immunoglobulin, plasmapheresis, staphylococcal Protein A immunoadsorption (Prosorba column), and chemotherapeutic agents (cytoxan and vincristine). Rituximab was given weekly at 375 mg/m2 for 4 doses. The drug was well tolerated and the patient remains in remission 9 months after completion of therapy.",

keywords = "Immune hemolytic anemia, Rituximab",

author = "Anat Galor and Timothy O'Brien",

year = "2003",

month = nov,

doi = "10.1007/BF02983558",

language = "English (US)",

volume = "78",

pages = "335--336",

journal = "International Journal of Hematology",

issn = "0925-5710",

publisher = "Springer Japan",

number = "4",

}

TY - JOUR

T1 - Rituximab Treatment for Relapsed Autoimmune Hemolytic Anemia in Evans Syndrome

AU - Galor, Anat

AU - O'Brien, Timothy

PY - 2003/11

Y1 - 2003/11

N2 - A case is reported of idiopathic relapsed autoimmune hemolytic anemia successfully treated with rituximab. A 43-year-old white male patient with past medical history of Evans syndrome was found to have recurrent autoimmune hemolytic anemia. Previous treatments included steroids, splenectomy, intravenous immunoglobulin, plasmapheresis, staphylococcal Protein A immunoadsorption (Prosorba column), and chemotherapeutic agents (cytoxan and vincristine). Rituximab was given weekly at 375 mg/m2 for 4 doses. The drug was well tolerated and the patient remains in remission 9 months after completion of therapy.

AB - A case is reported of idiopathic relapsed autoimmune hemolytic anemia successfully treated with rituximab. A 43-year-old white male patient with past medical history of Evans syndrome was found to have recurrent autoimmune hemolytic anemia. Previous treatments included steroids, splenectomy, intravenous immunoglobulin, plasmapheresis, staphylococcal Protein A immunoadsorption (Prosorba column), and chemotherapeutic agents (cytoxan and vincristine). Rituximab was given weekly at 375 mg/m2 for 4 doses. The drug was well tolerated and the patient remains in remission 9 months after completion of therapy.

KW - Immune hemolytic anemia

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=0348110645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0348110645&partnerID=8YFLogxK

U2 - 10.1007/BF02983558

DO - 10.1007/BF02983558

M3 - Article

C2 - 14686491

AN - SCOPUS:0348110645

VL - 78

SP - 335

EP - 336

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 4

ER -

Access to Document

10.1007/BF02983558